Pliant Therapeutics(PLRX) - 2025 Q3 - Quarterly Results

Exhibit 99.1 Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results Oncology Program • Phase 1 open-label trial of PLN-101095 in solid tumors has completed enrollment. PLN-101095 is an oral, small molecule, dual selective inhibitor of αvβ8 and αvβ1 integrins designed to overcome checkpoint resistance by blocking TGF-β activation in the tumor microenvironment. The Phase 1 open-label, dose-escalation trial of PLN-101095 as monotherapy and in combination with pembrolizum ...